Biogen stock is sharply lower Tuesday, March 31, 2026, despite a key regulatory win: the FDA approved a higher-dose regimen of Spinraza (nusinersen) for people living with spinal muscular atrophy. The pullback reflects a classic sell-the-news reaction after an anticipated catalyst, with investors weighing whether the approval is enough to meaningfully offset ongoing pressure from legacy neurology products and intensifying competition in SMA. (brecorder.com)

The newly approved higher-dose Spinraza regimen is aimed at improving outcomes for SMA patients, including addressing concerns that benefits can wane between maintenance doses for some individuals. Spinraza is a long-established product for Biogen, and the company has positioned the higher-dose option as a way to defend and potentially expand use, including in adults, where competition and switching dynamics have been challenging. (brecorder.com)

Even with approval in hand, investors are now focused on execution risk: the pace of adoption, payer coverage, and whether the higher-dose regimen can win share versus competing SMA options. With expectations already elevated into the decision window, the stock’s decline suggests near-term profit-taking and caution that the commercial lift may take time to show up in reported results. (fiercepharma.com)

Key near-term swing factors include early prescription trends for the higher-dose regimen, payer coverage policies, and management commentary on how the label translates into real-world switching and uptake. Investors will also track whether the SMA franchise stabilization meaningfully improves Biogen’s 2026 revenue trajectory, given the company’s broader effort to navigate erosion in older products while leaning on newer growth drivers and pipeline catalysts. (fiercepharma.com)